Arrowhead Pharmaceuticals (ARWR) saw its stock price surge 5.08% during intraday trading on Monday, reflecting strong investor optimism following a significant regulatory milestone.

The rally was driven by the U.S. FDA's approval of REDEMPLO (plozasiran), Arrowhead's first siRNA therapy for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS). This approval marks a pivotal transition for the company into a commercial-stage entity, with REDEMPLO offering a quarterly self-administered treatment option at home.

The FDA nod not only validates Arrowhead's RNAi platform but also opens new revenue streams, supported by recent licensing and collaboration deals, including a global agreement with Novartis worth up to $2 billion. This development has reshaped the company's investment narrative, shifting focus from partnership-dependent revenue to a more balanced business model.